Trending Down-0.0600 (-1.8293%)
  • Bid / Lots
    3.1700/ 3
  • Ask / Lots
    3.7200/ 3
  • Open / Previous Close
    3.2800 / 3.2800
  • Day Range
    Low 3.1700
    High 3.4500
  • 52 Week Range
    Low 2.7700
    High 6.4500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.28
09:32 ET4493.45
09:34 ET50003.25
09:36 ET10313.27
09:38 ET33253.45
09:41 ET14003.37
09:43 ET1253.44
09:45 ET1003.44
09:48 ET13613.4
10:01 ET14643.37
10:15 ET1003.3
10:17 ET19003.34
10:32 ET1003.29
10:33 ET1253.36
11:02 ET5003.226
11:06 ET21973.1801
11:08 ET1003.18
11:09 ET1003.18
11:13 ET1003.18
11:38 ET2503.21
12:00 ET1003.24
12:02 ET10373.3196
12:39 ET6593.28
12:41 ET1003.28
12:48 ET1003.3099
12:59 ET11003.24
01:15 ET5003.215
01:24 ET1003.25
02:09 ET5003.2105
02:11 ET18963.21
02:13 ET50003.21
02:15 ET1483.21
02:26 ET6453.21
02:40 ET1003.18
02:42 ET2003.2
02:44 ET8943.21
02:45 ET1003.21
02:56 ET2003.225
03:23 ET1253.29
03:41 ET1003.28
03:43 ET1523.27
03:48 ET2003.26
03:52 ET8563.2886
03:56 ET6253.26
03:57 ET11003.24
03:59 ET3003.22
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANIX
Anixa Biosciences Inc
United StatesATHA
Athira Pharma Inc
United StatesADVM
Adverum Biotechnologies Inc
United StatesDBTX
Decibel Therapeutics Inc
United StatesSPRB
Spruce Biosciences Inc
United StatesANTX
AN2 Therapeutics Inc
As of 2023-05-27

Company Information

Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

Contact Information

3150 Almaden Expy Ste 250SAN JOSE, CA, United States 95118


Chairman of the Board, Chief Executive Officer
Amit Kumar
President, Chief Financial Officer, Chief Operating Officer
Michael Catelani
Lead Independent Director
Lewis Titterton
Independent Director
Arnold Baskies
Independent Director
Emily Gottschalk

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.